This article is more than 5 years old. Information may no longer be current.

Intravitreal triamcinolone may be effective AMD treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MANNHEIM, Germany — Using intravitreal triamcinolone to treat eyes with exudative age-related macular degeneration helps improve visual acuity in a majority, a study here confirmed. Because some patients lost visual acuity after injection, the study authors suggest further research is warranted.

Jost B. Jonas, MD, and colleagues here with University Eye included 71 eyes of 67 patients with exudative age-related macular degeneration in a study to determine visual acuity (VA) increases after intravitreal injection of 25 mg of crystalline triamcinolone acetonide.

VA increased significantly from a mean of 0.16 to a mean of 0.23. Postoperative VA was highest 1 to 3 months after the injection. Of the eyes, 47 gained in VA and 11 lost VA. Intraocular pressure increased significantly from baseline, but decreased at the end of the follow-up.

The study is published in the April issue of British Journal of Ophthalmology.